King's College London at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
King's College London brings 9 presentations to ASH 2026 in New Orleans. Its research spans acute myeloid leukemia, CLL and lymphoma. It includes a first-in-class GCN2 inhibitor with venetoclax and azacitidine and measurable residual disease testing.
| Organization | ASH 2026 Attendance |
|---|---|
King's College London London, United Kingdom | |
Public research university in London with medical and life sciences faculties linked to King's Health Partners hospitals. | Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. Oral Sat Dec 12 4:00pm–5:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Oral Mon Dec 14 10:30am–12:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Find decision makers at King's College London
Tell us what you sell and we’ll find the people at King's College London most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction